BioCardia, Inc. (BCDA) Stock Score, Valuation & Financial Research

BioCardia, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BCDA

BioCardia, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.04. These figures are a research snapshot, not a buy or sell recommendation.

What BioCardia, Inc. does

BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

BioCardia is a clinical-stage biotechnology company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company generates revenue primarily through the fulfillment of performance obligations related to business partnerships and the potential future commercialization of its proprietary biotherapeutic delivery systems and cell therapy platforms.

Products and services

  • The company develops the CardiAMP and CardiALLO cell therapy platforms, as well as proprietary biotherapeutic delivery systems and the Morph DNA product portfolio for cardiovascular and pulmonary applications.

Brands and product families

  • CardiAMP — Investigational cell therapy platform for heart failure. Source
  • CardiALLO — Allogeneic MSC cell therapy platform for ischemic heart failure. Source
  • Morph DNA — Product portfolio for cardiovascular applications. Source

Customer types

Interventional cardiologists; Cardiac catheterization laboratories.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of certain components and clinical trial materials; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Large patent portfolio of issued and pending claims covering cell therapies and delivery systems Source
  • In-house manufacturing facility certified for clinical study production Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to fund operations Source
  • Uncertainty regarding the successful completion and regulatory approval of clinical trials Source

Sources: Company research source · Morph DNA

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BCDA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.04
Market capitalization:
15.48M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -7.34M
Free cash flow:
USD -7.44M
Cash:
USD 4.12M
Total debt:
USD 293K
EPS:
USD -0.76

What stands out

  • Free cash flow is USD -7.44M, negative for the stored period.
  • The balance sheet shows USD 4.12M of cash versus USD 293K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 3.82M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BCDA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BCDA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BCDA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BCDA to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BCDA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BCDA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.